Chongqing Pharscin Stock Hits Day Low Amid Price Pressure at CNY 13.64

Chongqing Pharscin Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 5.87% and reaching an intraday low of CNY 13.64. This performance stands in contrast to the China Shanghai Composite, which saw a slight increase of 0.04% on the same day. Over the past week, Chongqing Pharscin has faced a 6.55% decrease, while its performance over the last month shows a more favorable increase of 13.63%. However, the longer-term outlook remains challenging, with a year-to-date decline of 3.71% and a notable drop of 23.58% over the past year. The stock has also underperformed the China Shanghai Composite across various time frames, including the last three years. Financial metrics indicate a concerning trend, with net sales declining at an annual rate of 3.30% and operating profit decreasing by 20.21% over the past five years. The company currently holds a return on equity of 2.47% and a price-to-book ratio of 2.78, reflecting a high valuation relative to its earnings. Despite a dividend yield of 0.45%, the overall performance metrics suggest a challenging environment for Chongqing Pharscin Pharmaceutical Co., Ltd.